慢性疾病常导致代谢紊乱，引发合成抵抗和能量消耗增加，从而导致消瘦症。而消瘦症则会导致严重的临床后果，如生活质量下降、寿命缩短和医疗支出增加。现有的国际消瘦症诊断标准采用西方人群的阈值，这可能不适用于亚洲人因为体成分的差异。为了解决这个问题，亚洲消瘦症工作组（AWGC）成立了。该工作组由来自亚洲各国消瘦症研究和临床实践领域的专家组成，旨在针对亚洲地区制定消瘦症的诊断标准和重要临床结果的共识。AWGC由来自几个亚洲国家的消瘦症研究和临床实践领域的专家进行了三轮Delphi调查和五次会议以达成共识。讨论内容包括病因性疾病、消瘦症的必要诊断项目，包括主观和客观症状以及生物标志物，以及重要的临床结果。共识强调了消瘦症的多个诊断因素的重要性，包括慢性疾病，体重减轻或低体重指数，和以下至少一项：厌食、握力下降（男性<28kg，女性<18kg）或C-反应蛋白水平升高（>5mg/L [0.5mg/dL]）。AWGC提议消瘦症诊断中的重要体重变化为3-6个月内体重变化超过2%，并建议在诊断消瘦症时暂定体质指数低于21kg/m2的截断值。关键的临床结果被确定为死亡率、生活质量（如EQ-5D或食欲/消瘦症治疗功能评估）和功能状态（临床脆弱指数或Barthel指数），其中强调了患者报告的结果。AWGC的共识为亚洲人群提供了一个全面的定义和用户友好的消瘦症诊断标准。该共识有望推动未来的研究，并强化消瘦症的多学科管理方法。AWGC计划制定进一步的指南，以优化亚洲地区消瘦症的治疗、预防和护理。预计AWGC的标准将推动亚洲慢性共病和肿瘤的相关研究，从而进一步完善诊断标准。 © 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

Chronic diseases often lead to metabolic disorders, causing anabolic resistance and increased energy consumption, which result in cachexia. Cachexia, in turn, can lead to major clinical consequences such as impaired quality of life, shortened life expectancy, and increased healthcare expenditure. Existing international diagnostic criteria for cachexia employ thresholds derived from Western populations, which may not apply to Asians due to differing body compositions. To address this issue, the Asian Working Group for Cachexia (AWGC) was initiated. The AWGC comprises experts in cachexia research and clinical practice from various Asian countries and aims to develop a consensus on diagnostic criteria and significant clinical outcomes for cachexia in Asia. The AWGC, composed of experts in cachexia research and clinical practice from several Asian countries, undertook three-round Delphi surveys and five meetings to reach a consensus. Discussions were held on etiological diseases, essential diagnostic items for cachexia, including subjective and objective symptoms and biomarkers, and significant clinical outcomes. The consensus highlighted the importance of multiple diagnostic factors for cachexia, including chronic diseases, either or both weight loss or low body mass index, and at least one of the following: anorexia, decreased grip strength (<28 kg in men and <18 kg in women), or elevated C-reactive protein levels (>5 mg/L [0.5 mg/dL]). The AWGC proposed a significant weight change of 2% or more over a 3-6 month period and suggested a tentative cut-off value of 21 kg/m2 for low body mass index in diagnosing cachexia. Critical clinical outcomes were determined to be mortality, quality of life as assessed by tools such as EQ-5D or the Functional Assessment of Anorexia/Cachexia Therapy, and functional status as measured by the Clinical Frailty Scale or Barthel Index, with significant emphasis on patient-reported outcomes. The AWGC consensus offers a comprehensive definition and user-friendly diagnostic criteria for cachexia, tailored specifically for Asian populations. This consensus is set to stimulate future research and enhance the multidisciplinary approach to managing cachexia. With plans to develop further guidelines for the optimal treatment, prevention, and care of cachexia in Asians, the AWGC criteria are expected to drive research across chronic co-morbidities and cancer in Asia, leading to future refinement of diagnostic criteria.© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.